Relay Therapeutics Inc. stocks have been trading down by -11.44 percent after trial setback headlines raised serious investor concerns.
Click Here for a Millionaire's POV on Trading RLAY
SUBSCRIBE FOR ALERTSJOIN 50,000+ ACTIVE TRADERS
Key Takeaways
- Shares have dropped from the $17 area to near $13, putting RLAY into a short‑term downtrend on the daily chart.
- Intraday trading shows RLAY stabilizing around $13, with tight 5‑minute candles hinting at short‑term consolidation.
- Relay Therapeutics Inc. carries roughly $84M in cash and very low debt, giving traders confidence in its runway.
- RLAY continues to post heavy losses as it spends on research, keeping margins deeply negative and fueling volatility.
- With strong liquidity but steep cash burn, traders are watching for a break from the current consolidation range.
Live Update At 14:02:40 EDT: On Tuesday, April 28, 2026 Relay Therapeutics Inc. stock [NASDAQ: RLAY] is trending down by -11.44%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.
Quick Financial Overview
Relay Therapeutics Inc., traded under the ticker RLAY, is a classic high‑burn biotech story with a strong balance sheet but no profits in sight yet. Revenue is tiny at about $15.4M a year, and RLAY posts a profit margin near -1,800%. That is what aggressive drug development spending looks like in the numbers.
The latest quarterly report shows RLAY bringing in about $7M of revenue while losing roughly $54.9M, or about -$0.32 per share. Research and development expense sits near $55.4M for the quarter, dwarfing sales. For traders, that tells you the business is still very much in “build the pipeline” mode, not cash‑generation mode.
More Breaking News
- UAMY Stock Draws Trader Focus As Montana Mine Restarts Early
- BZAI Stock Slides As Traders Gauge High-Risk AI Setup
- BYND Stock Pops As Beyond Meat Pushes Into Drinks And Breakfast
- BTE Stock Draws Bullish Analyst Upgrades As Momentum Builds
On the flip side, the Relay Therapeutics balance sheet is loaded with assets. RLAY lists about $84M in cash and another ~$470.5M in investments, with total assets above $621M. Debt is tiny at around $28.7M long term, and key ratios like a 22.6 current ratio show strong liquidity. RLAY trades at a rich price‑to‑sales multiple, which keeps the stock sensitive to sentiment shifts and chart patterns.
Why Traders Are Watching RLAY Price Action
The RLAY chart has turned into a short‑term lesson in momentum shifts. Earlier in April, Relay Therapeutics shares were pushing up from the low $12s to highs above $17. On 2026/04/22, RLAY opened near $17.03 and held above $16 for most of the day, showing strong demand. But that push ran out of steam. From there, each session has stepped lower, with the stock closing at $13.23 on 2026/04/28.
For active traders, that drop from roughly $17 to the low $13s is a sizable pullback. It shows supply overwhelming demand and weak hands getting shaken out. The daily candles around 2026/04/23–2026/04/24 show RLAY failing to hold the mid‑$15s, setting up lower highs and confirming a short‑term downtrend.
Zoom into the 5‑minute chart and you see a different story. On the latest trading day, Relay Therapeutics opened near $14.79, popped toward $15 in the premarket, then sold off hard to just above $13. That early flush was followed by hours of tight, choppy trading between roughly $13.10 and $13.50. The midday range narrowed, and by the afternoon print, RLAY candles were small, volume‑like price moves compressed.
That pattern — sharp morning fade, then sideways grind — often signals short‑term consolidation after a fast selloff. Short sellers start locking in, dip buyers start probing, and day traders scalp both sides. With Relay Therapeutics still flush with cash but burning it quickly, the next strong move in RLAY is likely to come when the chart finally breaks this new range, up or down.
Conclusion
Relay Therapeutics Inc. sits in a familiar biotech spot: plenty of cash, little revenue, and a willingness to spend heavily on research. RLAY’s financials show about $84M in cash and more than $470M in investments, with low leverage and a current ratio above 22. That gives the company room to keep funding its pipeline. At the same time, quarterly losses around $54.9M and deeply negative returns on equity remind traders that dilution and volatility remain real risks.
On the chart, RLAY has gone from a strong push toward $17 to a decisive slide into the low $13s. Daily candles show a clear series of lower highs, while the intraday 5‑minute action highlights a tight consolidation band after heavy morning selling. For pattern‑driven traders, Relay Therapeutics is now a “wait and react” name: watch for a break above recent intraday highs for a momentum bounce, or a crack under $13 for potential further downside. As Tim Bohen, lead trainer with StocksToTrade says, “Preparation is half the trade. By the time the bell rings, my decisions are nearly made.” That mindset fits well with RLAY’s current setup, where detailed prior planning and clear levels can help traders react quickly when the price finally moves out of its range.
As Tim Sykes likes to say, “The chart doesn’t lie — traders do.” Relay Therapeutics Inc. and RLAY give a clean example of that principle right now. The financials explain why the stock is volatile; the price action tells you how traders are reacting day by day. For educational and research‑focused traders, RLAY is a useful case study in combining balance‑sheet strength, cash burn, and technical levels into one trading plan — always with a focus on cutting losses fast.
This is stock news, not investment advice. StocksToTrade News delivers real-time stock market updates tailored to highlight the key catalysts driving short-term price movements. Our coverage is designed for active traders and investors who thrive in fast-moving markets, with a focus on volatile sectors like penny stocks, AI stocks, Robinhood stocks and other momentum plays. From earnings reports and FDA approvals to mergers, new contracts, and unusual trading volume, we break down the events that can spark significant price action.
Looking to level up your trading game? Explore StocksToTrade, the ultimate platform for traders. With powerful tools designed for swing and day trading, integrated news scanning, and even social media monitoring, StocksToTrade keeps you one step ahead.
Check out our quick startup guide for new traders!
- How to Read Stock Charts: A Guide for Beginners
- Trading Plan: 6 Steps to Create One
- How To Create a Stock Watchlist
Ready to build your watchlists? Check out these curated lists:
Once your watchlist is set, take the next step and trade with confidence using StocksToTrade’s robust platform. Don’t miss out — grab your 14-day trial for just $7 and experience the edge you need to thrive in today’s fast-paced markets.